Sherwood CL, Daines MO, Price TJ, Vagner J, Boitano S. A highly potent agonist to protease-activated receptor-2 reveals apical activation of the airway epithelium resulting in Ca 2ϩ -regulated ion conductance.
THE AIRWAY EPITHELIUM is the first site of cellular contact for inhaled allergens and other insults. It provides a barrier to protect underlying submucosa from inhalation threats and orchestrates critical aspects of airway innate immunity, such as inflammation, airway remodeling, and mucociliary clearance (16, 34) . A subset of inhaled allergens (e.g., house dust mites, cockroaches, and various fungi) has been associated with the onset and pathogenesis of allergic asthma (36, 40) . Allergic asthma is a chronic disease associated with airway remodeling that includes inflammation, secretory alterations, and airway hyperreactivity culminating in airway obstruction (20) . Although allergens associated with asthma (i.e., asthmagens) are quite diverse, many of them contain proteases that can interact with the airway epithelium through a variety of mechanisms that include the activation of protease-activated receptor-2 (PAR 2 ) (22) . PAR 2 is a G protein-coupled receptor (GPCR) belonging to a family of GPCRs composed of four members (2) . Unlike typical GPCRs, PAR ligand activation sequences are contained within the extracellular portion of the GPCR. Proteolytic cleavage of the NH 2 -terminus reveals the tethered ligand [SLIGKV for humans and SLIGRL for rodents (30) ], which binds an activation pocket, leading to cellular signaling cascades. Exogenous asthmagen-associated proteases that have been demonstrated to activate PAR 2 include those from the house dust mite, cockroaches, and fungi (22, 23, 32) . Individuals with asthma are often sensitized to these protease-containing allergens; thus, understanding roles for PAR 2 in normal and pathological airway physiology have been an intense research focus (2, 17, 21, 33, 41) .
The full impact of PAR 2 in allergic asthma is quite complex. PAR 2 activation has been linked to long-term, detrimental airway inflammation and hypersecretion as well as beneficial bronchodilation (7, 8, 10, 12, 19, 38, 42) . It has been suggested that these diametrically opposed outcomes may be separable by the activation of separate signaling pathways downstream of PAR 2 (43) . In studies examining more rapid responses in the airway epithelium, PAR 2 has been linked to changes in airway epithelial ion conductance (5, 9, 25, 31, 35, 37) . Interestingly, studies that have uncovered roles for PAR 2 in ion conductance changes across the airway epithelium have focused on the basolateral activation of PAR 2 (1, 24, 25, 35) . This has occurred despite immunocytochemical evidence for apical expression of PAR 2 in mouse and human tissues (6, 8, 25) , where the receptor would most likely interact with inhaled proteases in healthy individuals. Further complicating the role of PAR 2 in airway epithelial ion movement is the finding that, in some mouse strains, PAR 2 ligands (i.e., SLIGRL-NH 2 ) have been shown to activate ion conductance changes that appear independent of PAR 2 (1) .
In the present study, we evaluated the potency and specificity of a recently developed, lipidated PAR 2 -regulated ion channels consistent with a subsequent apical efflux of Cl Ϫ . The availability of potent and specific PAR 2 agonists suggests that apical PAR 2 activation can contribute to mucociliary clearance and thus aid in the rapid clearing of asthmagens from healthy airways.
MATERIALS AND METHODS
Materials. Cellgro DMEM:F-12 was from Mediatech (Manassas, VA). Lechner and LaVeck basal media, HBSS, glutamax, penicillin, and streptomycin were from InVitrogen (Carlsbad, CA). Fibronectin, collagen type I, and Nu-Serum were from Becton-Dickinson (Franklin Lakes, NJ). FBS and clotrimazole were from Sigma-Aldrich (St. Louis, MO). CaCCinh-A01 was from Tocris Bioscience (Bristol, UK). Semipermeable filters were Corning Costar 6.5-mm Transwell filters with a 0.4-m Pore Polyester Membrane Insert (Lowell, MA). All other chemicals were from Sigma-Aldrich or Fisher Scientific (Pittsburgh, PA).
Tissue culture methods. Animal protocols were approved by the Institutional Animal Care and Use Committee of The University of Arizona. Primary mouse tracheal epithelial (MTE) cells were cultured as previously described (39) . C57Bl/6 wild-type and PAR 2 Ϫ/Ϫ mice on a C57Bl/6 background were used for these cultures. Isolated primary MTE cell cultures for digital imaging microscopy were seeded onto glass coverslips coated with rat tail collagen (11), cultured at 37°C with 5% CO2, and fed every other day in full culture medium. Although these cells establish cell junctions, they do not become well differentiated. MTE cells used in Ussing chamber experiments were seeded onto 6.5-mm semipermeable filters coated with a collagen-fibronectin-BSA matrix and cultured at 37°C with 5% CO2. MTE cells were grown in full culture medium to allow for confluent monolayers. After cell monolayers reached a TER of Ͼ500 ⍀·cm 2 (ϳ5 days), apical media were removed to establish an air interface, and media were changed to a 1:1 mixture of DMEM and Ham's F-12, 1% penicillin-streptomycin, and 2% Nu-Serum. These cells become a mixed population of well-differentiated cells with clearly established cilia.
[ ]i twofold or more. Ussing chamber experiments. MTE cells on 6.5-mm Transwell filters were mounted in an EasyMount Ussing chamber system (Physiologic Instruments, San Diego, CA) and bathed on both sides with Krebs-Ringer buffer containing (in mM) 115 NaCl, 25 NaHCO3, 0.4 KH2PO4, 2.4 K2HPO4, 1.2 CaCl2, and 1.2 MgCl2 with 10 glucose. Bath solutions were continuously circulated with a gas lift by bubbling with 95% air and 5% CO2 at 37°C (pH 7.4). MTE cell monolayers were either current clamped and observed for changes in TER or voltage clamped and monitored for changes in short circuit current (I sc) and TER with a multichannel voltage/current-clamp VCC MC8 (Physiologic Instruments). For current-clamp experiments, MTE monolayers were clamped to 0 A, and a 5-A pulse of 200-ms duration was imposed every 10 s to monitor TER. Changes in I sc from those experiments were calculated using Ohm's law. Changes in TER (⌬TER) were calculated from the difference between the TER measurement at baseline and the peak measurement change after the addition of agonist. In voltage-clamp experiments, MTE cell monolayers were clamped to 0 mV, and a 5-mV pulse of 200-ms duration was imposed every 10 s. Changes in I sc (⌬Isc) were calculated from the difference between the initial I sc measurement at baseline and the peak measurement change after the addition of agonist. Data were analyzed using Acquire and Analyze software (version 2.3, Physiologic Instruments).
Statistics. An unpaired Student's t-test was used for comparisons between two data sets. One-way ANOVA with Tukey's multiplecomparison test was used for data sets with more than two comparisons. P values of Ͻ0.05 were used to establish significant differences between data sets. Values are expressed as means Ϯ SE unless otherwise noted. Fig. 2, A and B) . The observed loss in TER after the addition of 2at-LIGRLO(PEG 3 -Pam)-NH 2 could not be explained by a substantial breakdown in the epithelial barrier as fluorescently labeled permeability markers as small as 600 Da did not significantly penetrate the epithelial barrier of wild-type cells (data not shown). The loss in TER, however, was concurrent with a transient increase in calculated I sc in wild-type epithelia (6.8 Ϯ 1.5 A/cm 2 , n ϭ 6; Fig. 2C  and D) . In contrast, the calculated change in I sc in response to 2at-LIGRLO(PEG 3 -Pam)-NH 2 from PAR 2 Ϫ/Ϫ epithelia was negligible (1.0 Ϯ 0.18 A/cm 2 , n ϭ 4; Fig. 2, C and D Fig.  3, A-C) . A slightly larger but not significantly different response from SLIGRL-NH 2 was observed after the apical addition of 2at-LIGRL-NH 2 (⌬I sc : 5.27 Ϯ 0.394 A/cm 2 and ⌬TER: Ϫ42.00 Ϯ 14.0 ⍀·cm 2 , n ϭ 3; Fig. 3, A-C , n ϭ 6; Fig. 3, A-C were voltage clamped and pretreated apically with 10 M Ca 2ϩ -activated Cl Ϫ channel (CaCC) inhibitor for 3 min followed by the apical addition of 10 M 2at-LIGRLO(PEG 3 -Pam)-NH 2 (Fig. 6, A and B) . CaCC inhibitor significantly (Fig. 6, E and F) . In these experiments, the response to 2at-LIGRLO(PEG 3 -Pam)-NH 2 was almost completely abolished (⌬I sc : 0.017 Ϯ 0.017 A/cm 2 and ⌬TER: Ϫ0.533 Ϯ 0.393 ⍀·cm 2 , n ϭ 3; Fig. 6G ).
RESULTS

High
DISCUSSION
In the present study, we show, for the first time in primary airway epithelial cells, the robust apical activation of PAR 2 leading to a transient decrease in TER accompanied by an increase in Ca 2ϩ -regulated Cl Ϫ and K ϩ conductances. These changes could only be observed with the recently developed, high-potency, lipidated PAR 2 ligand 2at-LIGRLO(PEG 3 -Pam)-NH 2 (14) . Apically positioned PAR 2 in the conducting airway epithelium is ideally located to detect endogenous proteases that can accompany allergen inhalation. We postulated that the transient changes in ion conductance could provide a temporary increase in airway surface liquid. This would be complemented by Ca 2ϩ -induced increases in ciliary beat (13) . Thus, initial activation of PAR 2 in the lumenal airway could aid innate immune function via rapid, local upregulation of mucociliary clearance. PAR 2 is expressed throughout the airway epithelium. Its activation after asthmagen exposure has been associated with both protective affects via bronchorelaxation (7, 8, 10, 19) and detrimental effects (e.g., cytokine release and subsequent chronic inflammation) in animal models of asthma (12, 38, 42) . It has come to light in recent work that this dichotomy in PAR 2 activation effects may be due to dual signaling pathways downstream of PAR 2 , namely, G q -dependent Ca 2ϩ signaling and G protein-independent ␤-arrestin signaling (29) . Similar signaling has been reported for another GPCR targeted in asthma treatment, ␤-adrenergic receptor (␤AR) signaling (43) . Because of the diametrically opposed responses, continued development of novel, potent, efficacious, and (potentially) biased signaling drugs that affect PAR 2 or ␤AR are highly desirable. Recent progress in improving PAR 2 ligand potency and efficacy has occurred through the lipidation of the known PAR 2 agonists (4, 14) . Such lipidated compounds, which include 2at-LIGRLO(PEG 3 -Pam)-NH 2 used in this study, have orders of magnitude increased potency with improved selectivity for PAR 2 over traditionally used peptides (e.g., SLIGRL-NH 2 ) or peptidomimetics (e.g., 2at-LIGRL-NH 2 or 2-furoyl-LIGRLO-NH 2 ).
In the present study, we characterized the use of lipidated PAR 2 ligands in the activation of primary cultured MTE cells. Interestingly, apical application of the lipidated PAR 2 agonist to cultured MTE cells initiated a Ca 2ϩ flux with a markedly higher EC 50 (835 nM) and wider 95% confidence interval (261 nM-2.68 M) than those observed in an immortalized human bronchial airway cell line (16HBE14o-cells; EC 50 : 3.95 nM, 95% confidence interval: 3.43-4.55 nM). The need for higher concentrations of lipidated PAR 2 ligands in primary cultured cells was not unexpected as it is not uncommon to observe differences in immortalized and primary cultured cells. However, this change in activity emphasizes the need for potent and efficacious ligands to evaluate roles for apically expressed PAR 2 in the airway. As a measure of specificity, PAR 2 Ϫ/Ϫ cells did not respond to the lipidated ligand with a transient change in [Ca 2ϩ ] i or ion flux. Roles for PAR 2 in airway ion conductance in the mouse or human airway epithelium have traditionally been evaluated using basolateral application, in part due to the lack of response to activating peptides and/or peptidomimetics when applied apically (9, 25, 28, 31, 35, 37, 45) . Our results examining basolaterally activated PAR 2 were similar to previous findings in that all of the PAR 2 ligands tested [SLIGRL-NH 2 , 2at-LIGRL-NH 2 , and 2at-LIGRLO(PEG 3 -Pam)-NH 2 at 10 M] evoked rapid, transient changes in TER and I sc . It was somewhat surprising to us that a more robust response with the lipidated compound compared with traditional activating peptide and/or peptidomimetic was not observed after basolateral activation. We also noted a slightly different shape in the representative traces from those experiments with 2at-LIGRLO(PEG 3 -Pam)-NH 2 , which required more time to develop a full response in Ussing chamber experiments. It is likely these changes represent the lipid sequence interacting with the tissue culture filter and/or collagen during application and thus hindering presentation of the agonist to the receptor on the basolateral membrane.
Proteases in asthmagens have been shown to alter the barrier function of healthy and asthmatic airways (22, 27, 44) . Furthermore, remodeled airway epithelium in asthmatics includes a reduction in barrier function (20) . Thus, basolateral activation of PAR 2 could be relevant after extended asthmagen exposure or in diseased or compromised airways. However, basolateral activation of PAR 2 by inhaled asthmagens would not necessarily be expected in a healthy individual. A further caveat of interpreting basolateral PAR 2 activation is the demonstration in model epithelial cells of distinct pools of PAR 2 that display differential signaling when activated at apical or basolateral membranes (26) . As mentioned above, there exists limited data using traditional activating peptides (e.g., SLIGRL-NH 2 ) and peptidomimetics (e.g., 2at-LIGRL-NH 2 ) applied to the apical airway epithelial membrane. Although Cl Ϫ current was observed after high concentrations (30 M) of SLIGRL-NH 2 to the mouse (BALB/c) trachea, these changes were attributed to nonspecific neurokinin-1 receptor activation (1) . Using the potent and selective lipidated compound 2at-LIGRLO(PEG 3 -Pam)-NH 2 , we were able to demonstrate, for the first time, apical PAR 2 activation in primary mouse tracheal epithelia that resulted in transient changes in TER and I sc . To rule out the possibility that the lipidated agonist disrupted the epithelium and gained access to the basolateral side for activation, we repeated our recordings with 10 M concentrations of SLIGRL-NH 2 and O(PEG 3 -Pam)-NH 2 . As with 10 M SLIGRL-NH 2 alone, no epithelial response was observed.
Apical activation of PAR 2 -dependent Ca 2ϩ -regulated Cl Ϫ and K ϩ currents that could drive secretion in our well-differentiated MTE cells is consistent with the basolateral activation of the whole mouse trachea previously reported (25) . Basolateral activation of primary human cells from absorptive airway also displayed Ca 2ϩ -regulated Cl Ϫ and K ϩ currents that were supplemented with cAMP-dependent ion flow (9, 24, 25) . These differences can be attributed to known differences in ion channel and transporter expression in the mouse and human airway (25) . We conclude from these data that although PAR 2 is differentially sensitive in the apical and basolateral absorptive airway epithelium, activation results in similar, transient Ca 2ϩ dependent Cl Ϫ and K ϩ currents that temporarily provide a secretory phenotype (i.e., net Cl Ϫ efflux). It would be interesting to use the high-potency lipidated PAR 2 agonist to determine if apical activation of secretory airway epithelial model cells [e.g., Calu-3 cells (31, 37, 45) ] would result in similar signaling as we observed above or differential signaling, as observed in human colon epithelial models (26) .
In summary, we have shown apical activation of PAR 2 on primary airway epithelial cells using the highly potent and specific lipidated peptidomimetic 2at-LIGRLO(PEG 3 -Pam)-NH 2 . To our knowledge, this is the first time activation of PAR 2 has been demonstrated at the apical surface of airway epithelial cells. Using highly potent and specific agonists to PAR 2 we can isolate receptor-specific contributions to airway epithelial function not previously possible. A plausible physiological implication for PAR 2 activation at the apical airway surface that results in Cl Ϫ efflux is an increase in airway surface liquid. Increases in airway surface liquid would serve to aid in flushing out noxious stimuli such as inhaled asthmagens in a healthy individual.
